Wounds. 2026 Sep;38(9):224-236. doi: 10.25270/wnds/25122.
ABSTRACT
BACKGROUND: Chronic wounds present a significant health concern due to their prolonged healing time, risk of severe complications, and the burden they place on patients, health care providers, and the health system.
OBJECTIVE: To prospectively evaluate an advanced wound care treatment that delivers catalytic technology (through polymers engineered to replicate the extracellular matrix) and facilitates copper-dependent cellular signaling pathways involved in wound healing.
METHODS: This interrupted time series was a multisite, within-patient controlled, clinical evaluation of the catalytic technology involving 25 participants each with at least 1 chronic wound (pressure injury, diabetic foot ulcer, or venous leg ulcer). Participants received standard wound care for 28 days (control phase), followed by 28 days with the catalytic technology replacing the primary dressing (intervention phase). Wound percent area reduction (PAR) was assessed weekly.
RESULTS: The average wound age prior to study inclusion was 84 weeks. In the control phase, the average PAR was -1.0%. In the intervention phase, the average PAR was 56.6%, showing that the catalytic technology accelerated wound healing (total overall change, 57.6%; P < .0001; > 95% power). The catalytic technology also demonstrated a safety profile equivalent to that of current state dressings.
CONCLUSION: When used in combination with standard of care practices to promote wound healing, the catalytic technology was shown to be an effective tool in the treatment of chronic wounds compared with other available wound dressings.
PMID:42873834 | DOI:10.25270/wnds/25122